Cosciens Biopharma Says Phase 3 DETECT-Trial Top-line Results Show Efficacy Standpoint Not Met
Cosciens Biopharma Says Phase 3 DETECT-Trial Top-line Results Show Efficacy Standpoint Not Met
Cosciens Biopharma表示，III期DETECt試驗的首要結果顯示從療效的角度來看並未達到要求
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間